EGPA: Highlighting the Patient Journey to Improve the Differential Diagnosis and Accelerate the Initiation of Guideline-Based Care

Tune in to the stream at 6:30 pm ET HERE

Overview

Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic necrotizing vasculitis occurring in asthmatic individuals. Vessel inflammation and eosinophilic proliferation are the hallmarks of the disease and the main cause of organ damage. Although EGPA has a low incidence and prevalence, there appears to be a substantial morbidity and health care burden associated with it. Approximately 35% of patients relapse less than 5 years after they achieve initial remission.

The clinical manifestations of EGPA are diverse and can have differing responses to treatment. New guidelines were published for the treatment of EGPA by the American College of Rheumatology/Vasculitis Foundation in 2021. New insights into the pathophysiology of EGPA continue to allow for the discovery of new targets for treatments, including eosinophils and B cells. This continuing education activity will update clinicians on new developments in understanding of the underlying pathophysiology of EGPA and emerging therapeutic targets.

Learning Objectives

Upon completion of this activity, learners should be able to:

• Describe pathophysiological pathways underlying EGPA
• Implement diagnostic strategies to identify patients with EGPA
• Apply evidence-based guidelines to the management of patients with EGPA

Program Chair

Anisha Dua, MD, MPH

To view full profile, click on the Program Chair tab above.

Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.